A method for the manufacture of clevidipine by reaction of an inorganic salt of 4-(2,3-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridine-carboxylate and chloro methyl butyrate.

Description

9 parts

›This application is a 371 of PCT/SE99/02155 filed…

This application is a 371 of PCT/SE99/02155 filed Nov. 22, 1999.

›FIELD OF THE INVENTION

The present invention relates to an improved method for the manufacture of clevidipine (butyroxymethyl methyl 4-(2′,3′-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) via the route of reacting 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylic acid with chloromethyl butyrate.

›PRIOR ART

WO 95/12578 discloses a method for the preparation of clevidipine using as reactants 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylic acid. The disclosed method has several drawbacks.

›DISCLOSURE OF THE INVENTION

It has now been found that clevidipine, which is a short-acting calcium-channel blocker, can be prepared in a manner that is faster, reduces the amount of byproducts, is more environmentally sound and gives a better yield than the process disclosed in WO 95/12578. It also increases the stability of one of the intermediates allowing it to be isolated and stored without drying.

The method according to the invention uses an inorganic salt instead of the neutral form of carboxylic acid.

The method which is schematically outlined below is characterized by reaction of compound A, wherein A + is a positively charged inorganic ion with chloromethyl butyrate to obtain clevidipine.

Compound A is reacted with chloromethyl butyrate optionally in the presence of a corresponding hydrogen carbonate (preferable KHCO 3 ) in refluxing acetonitrile. A + is preferably potassium or sodium, most preferably potassium. Preferably the inorganic salts are removed by filtration and the product is crystallized. The crystallization can be performed for instance by the addition of isopropanol and water with subsequent cooling. It can also be crystallized by exchanging solvent from acetonitrile to a mixture of alcohol, such as ethanol or isopropanol, preferably ethanol, and water with repeated evaporations. In the further purification of the product the crystals are washed with a mixture of water and ethanol or isopropanol. The product can be dissolved in refluxing isopropanol, crystallized by cooling, isolated by filtration and finally washed with a water and isopropanol mixture.

In a preferred embodiment Compound A is reacted with chloromethyl butyrate (1.2-2.8 eq., preferably 1.4-1.6 eq.). The reactants are charged together with potassium hydrogen carbonate (1.5-0.4 eq., preferable 0.8-0.6 eq.) and the solvent acetonitrile (3-12 ml/g of Compound A).

Preparation of Compound A starting material

Cyanoethyl methyl 4-(2′,3′-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate is reacted with potassium hydroxide or other suitable hydroxide e.g. sodium hydroxide in isopropanol over night at room temperature. Some of the solvent can be evaporated off to increase the yield or the product is isolated direct without any evaporation and washed with isopropanol.

WORKING EXAMPLES

›Examples4

›Example 1

Potassium 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate (10.6 kg 27 mol; 1 eq), acetonitrile (63 L) and chloromethyl butyrate (5.8 kg ,42 mol; 1.6 eq) were heated to reflux. After 3.5 h at reflux the inorganic salts were filtered off and washed with warm acetonitrile (25 L). The temperature of the solution was adjusted to 50° C. and then 2-propanol (17 kg) and water (110 kg) were added to the solution. The slurry was left over night (8.5 h) at 25° C. before the product was isolated and washed with a mixture of 2-propanol (16 kg) and water (28 kg). This gave clevidipine-crude (11.0 kg, 90%) as a white to slightly yellowish solid. LC-purity 99.58%, LC-assay 98.93% (w/w)

›Example 2

Potassium 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate (6.7 g, 15 mmol; 1 eq), KHCO 3 (0.9 g, 9 mmol; 0.6 eq), acetonitrile (50 ml) and chloromethyl butyrate (2.7 ml, 21 mmol; 1.4 eq) were heated to reflux. After 4.5 h at reflux the inorganic salts were filtered off and washed with warm acetonitrile (20 ml). The solvent was exchanged from acetonitrile to ethanol:water (˜35 ml, 2:1). The solution was left over night (17 h) at ambient temperature before the product was isolated and washed with a mixture of ethanol:water (3*5 g, 3:1). This gave clevidipine-crude (5.2 g, 76%) as a white to slightly yellowish solid. LC-purity 99.2%

›Example 3

Sodium 4-(2′,3′-dichlorophenyl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate (7.0 g, 15 mmol; 1 eq), NaHCO 3 (0.8 g, 9 mmol; 0.6 eq), acetonitrile (50 ml) and chloromethyl butyrate (2.7 ml , 21 mmol; 1.4 eq) were heated to reflux. After 5 h at reflux the inorganic salts were filtered off and washed with warm acetonitrile (20 ml). The solvent was exchanged from acetonitrile to ethanol:water (˜35 ml, 2:1). The solution was left over night (17 h) at ambient temperature before the product was isolated and washed with a mixture of ethanol:water (3*5 g, 3:1). This gave clevidipine-crude (5.1 g, 74%) as a white to slightly yellowish solid. LC-purity 98.8%

›Example 4

Clevidipine crude (7.5 g, 16 mmol) and 2-propanol (38 g) were heated to reflux. The temperature was adjusted to 40° C. and water (48 g) was added. The solution was left over night at ambient temperature before the product was isolated and washed with a mixture of 2-propanol:water (2*10 g (45:55% w/w)). This gave clevidipine (7.2 g, 96%) as a white to slightly off white solid. LC-purity 99.9%

1 of 9 part labels are ours — the grant heads the rest

Claims as granted

12 claims

Classifications

6 codes

IPC · International Patent Classification

Section A — Human necessities

A61P9/12
A61K31/4422

Section C — Chemistry; metallurgy

C07D211/90

USPC · US Patent Classification

546/322546/321514/356

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.3 y

827 days filing → grant

Office actions

non-final + final

Responses

no RCE

Examiner

Alan L. Rotman

art unit 1625 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 4 back · 7 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.